- Home
- ACCL vs VTVT Comparison
ACCL vs VTVT Comparison
Compare ACCL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCL
- VTVT
- Stock Information
- Founded
- ACCL 2009
- VTVT 2015
- Country
- ACCL Hong Kong
- VTVT United States
- Employees
- ACCL N/A
- VTVT N/A
- Industry
- ACCL Professional Services
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- ACCL Consumer Discretionary
- VTVT Health Care
- Exchange
- ACCL Nasdaq
- VTVT Nasdaq
- Market Cap
- ACCL 57.8M
- VTVT 54.4M
- IPO Year
- ACCL 2025
- VTVT 2015
- Fundamental
- Price
- ACCL $3.94
- VTVT $31.31
- Analyst Decision
- ACCL
- VTVT Strong Buy
- Analyst Count
- ACCL 0
- VTVT 3
- Target Price
- ACCL N/A
- VTVT $37.00
- AVG Volume (30 Days)
- ACCL 113.8K
- VTVT 11.5K
- Earning Date
- ACCL 12-05-2025
- VTVT 11-06-2025
- Dividend Yield
- ACCL N/A
- VTVT N/A
- EPS Growth
- ACCL 2.91
- VTVT N/A
- EPS
- ACCL 0.08
- VTVT N/A
- Revenue
- ACCL $4,888,824.00
- VTVT $17,000.00
- Revenue This Year
- ACCL N/A
- VTVT N/A
- Revenue Next Year
- ACCL N/A
- VTVT N/A
- P/E Ratio
- ACCL $52.36
- VTVT N/A
- Revenue Growth
- ACCL 11.91
- VTVT N/A
- 52 Week Low
- ACCL $2.10
- VTVT $13.15
- 52 Week High
- ACCL $5.00
- VTVT $33.16
- Technical
- Relative Strength Index (RSI)
- ACCL N/A
- VTVT 68.37
- Support Level
- ACCL N/A
- VTVT $29.40
- Resistance Level
- ACCL N/A
- VTVT $33.16
- Average True Range (ATR)
- ACCL 0.00
- VTVT 1.88
- MACD
- ACCL 0.00
- VTVT 0.34
- Stochastic Oscillator
- ACCL 0.00
- VTVT 74.76
About ACCL Acco Group Holdings Limited Ordinary Shares
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.